Q2 2024

Filed Aug 13, 2024 · 10-Q · 44 days after period end · 0000950170-24-096148

Q2 2024 · 10-Q

Revenue—

Net Income

-$11.70M

N/M vs Q2 2023

EPS Diluted

-$0.18

N/M vs Q2 2023

Operating Income-$14,263,000N/M

Operating Cash Flowderived-$8,902,000N/M

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2020
Revenue	—	$2.09M	$2.51M	$2.21M
Net Income	-$11.70M	-$11.11M	-$2.08M	-$897.00K
EPS Diluted	-$0.18	-$0.40	—	-$0.01

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR